Related references
Note: Only part of the references are listed.Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study
Michael Borte et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2023)
Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies
Stephen Jolles et al.
LEUKEMIA & LYMPHOMA (2022)
Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies
Zhaoyang Li et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2022)
Update on real-world use of facilitated subcutaneous immunoglobulin and immune globulin subcutaneous (human) 20% solution in patients with immunodeficiencies: poster extracts from the 19th Biennial Meeting of the European Society for Immunodeficiencies
Michael Borte et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2021)
Secondary immunodeficiencies An overview
Karen S. Tuano et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)
A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants
Clara Monleon Bonet et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2020)
Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies
Il-Kang Na et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management
Smita Y. Patel et al.
FRONTIERS IN IMMUNOLOGY (2019)
Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis
Maria Dimou et al.
ANTICANCER RESEARCH (2018)
Experiences of the burden of treatment-Patient reports of facilitated subcutaneous immunoglobulin treatment in adults with immunodeficiency
Christina Petersson et al.
JOURNAL OF CLINICAL NURSING (2018)
Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study
Marcel Reiser et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases
Richard L. Wasserman
IMMUNOTHERAPY (2017)
Update on the use of immunoglobulin in human disease: A review of evidence
Elena E. Perez et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach
S. Jolles et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
Secondary antibody deficiency - causes and approach to diagnosis
Sapna Srivastava et al.
CLINICAL MEDICINE (2016)
Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies
Igor-Wolfgang Blau et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2016)
Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion
Carlo Agostini et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2016)
Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability
Richard L. Wasserman et al.
IMMUNOTHERAPY (2016)
Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
Richard L. Wasserman et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2016)
Facilitated subcutaneous immunoglobulin (fSCIg) therapy-practical considerations
M. Ponsford et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2015)
Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients
Nicolo Compagno et al.
HAEMATOLOGICA (2014)
Primary vs. Secondary Antibody Deficiency: Clinical Features and Infection Outcomes of Immunoglobulin Replacement
Sai S. Duraisingham et al.
PLOS ONE (2014)
Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency
Richard L. Wasserman et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease
Richard L. Wasserman et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
Improved Quality of Life, Immunoglobulin G Levels, and Infection Rates in Patients with Primary Immunodeficiency Diseases during Self-Treatment with Subcutaneous Immunoglobulin G
Melvin Berger et al.
SOUTHERN MEDICAL JOURNAL (2010)
Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration
Gregory I. Frost
EXPERT OPINION ON DRUG DELIVERY (2007)
A recombinant human enzyme for enhanced interstitial transport of therapeutics
L. H. Bookbinder et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Share Paper
